论文部分内容阅读
Chimerix制药公司近日公布数据称,免疫力低下的腺病毒(AdV)严重感染患者在经该公司研发的代表性抗病毒化合物CMX001(化学名:十六烷丙氧基西多福韦)治疗2周后,绝大部分受试者体内病毒载量较用药前降低
According to a recent report by Chimerix Pharmaceuticals, patients with severe immunocompromised adenovirus (AdV) were treated with CMX001, a representative antiviral compound developed by the company (Cetylpropoxy Cidofovir) for 2 weeks After the vast majority of subjects in vivo viral load decreased compared with before treatment